There shall be twelve directors who, in addition to five officers, shall constitute the Board of Directors. There shall be balanced representation among academia, government and industry and voluntary health organizations on the Board of Directors. The Board of Directors shall manage the property and affairs of the Organization subject to these Bylaws.

OFFICERS
	President Thomas P. Sutula, M.D., Ph.D. University of Wisconsin - Madison		President Elect TBD		Secretary TBD
	Treasurer Robert W. Hamill, M.D. University of Vermont College of Medicine, Department of Neurological Sciences		Immediate Past President Martha Morrell, M.D. NeuroPace, Inc
BOARD OF DIRECTORS
	Amy S. Chappell, M.D. Naples, FL		O’Neill D’Cruz, MD, MBA, FAAN OD Consulting and Neurological Services, PLLC
	Stewart A. Factor, DO Emory University School of Medicine		Toby Ferguson, MD, PhD Biogen Idec, Inc
	Bennett L, Lavenstein, MD Co-Chair Children’s Hospital Medical Center		John R. Richert, MD Richert Partners
	Steven Schachter, MD CIMIT/Harvard Medical School
EX-OFFICIO BOARD MEMBERS
	Development Committee Chair Martha Morrell, M.D. NeuroPace, Inc		Neurotherapeutics® Editor-in-Chief M. Maral Mouradian, MD Rutgers University		Program Committee Chair Stewart A. Factor, DO Emory University School of Medicine
	NIH Blueprint Course Liaison Barbara Slusher, PhD, MAS John Hopkins Brain Science Institute		Federal Liaison Amir Tamiz, PhD NIH, NINDS, OTR		Program Committee Co-Chair C. Anthony Altar, PhD Neuro Drug Consulting
	Communications Terrie Blalock, RN, MS TBlalock Consulting		Communications David Shoup The Curry Rockefeller Group
EXECUTIVE STAFF
	Executive Director Jessica Keenan Smith ASENT